My Cart

0 Item(s): $0.00

You have no items in your shopping cart.

Buy Estramustine

Buy Estramustine


Estramustine phosphate sodium, an antineoplastic agent, is an off-white powder readily soluble in water. EMCYT Capsules are white and opaque, each containing estramustine phosphate sodium as the disodium salt monohydrate equivalent to 140 mg estramustine phosphate, for oral administration. Each capsule also contains magnesium stearate, silicon dioxide, sodium lauryl sulfate, and talc. Gelatin capsule shells contain the following pigment: titanium dioxide.

Chemically, estramustine phosphate sodium is estra-1,3,5(10)-triene-3,17-diol(17β)-,3-[bis(2- chloroethyl)carbamate] 17-(dihydrogen phosphate), disodium salt, monohydrate. It is also referred to as estradiol 3-[bis(2-chloroethyl)carbamate] 17-(dihydrogen phosphate), disodium salt, monohydrate.


This medication is used to treat some types of prostate cancer. In the body, estramustine breaks down into estrogens (estrone, estradiol) and a type of cancer drug (estromustine). This medication is thought to work by increasing estrogens, which interfere with prostate cancer, and by slowing/stopping the growth of cancer cells.

How Estramustine Works

Estramustine is a medicine that consists of the combination of two types of drugs — a hormone called estrogen and a chemotherapy drug called nitrogen mustard. It is used for the treatment of patients who suffer from prostate cancer that is no longer responding to hormone treatment. While healthy cells normally reproduce and die, cancerous cells divide and continue uncontrollably to grow. Estramustine’s mechanism of action is based on stopping the cancerous cells from dividing into two new cells, which results in a blockage of tumor growth as well as of other hormones in the body that promote cancer growth.

Dosage and administration

The recommended daily dose is 14 mg per kg of body weight (ie, one 140 mg capsule for each 10 kg or 22 lb of body weight), given in 3 or 4 divided doses. Most patients in studies in the United States have been treated at a dosage range of 10 to 16 mg per kg per day.

Patients should be instructed to take EMCYT Capsules at least 1 hour before or 2 hours after meals. EMCYT should be swallowed with water. Milk, milk products, and calcium-rich foods or drugs (such as calcium-containing antacids) must not be taken simultaneously with EMCYT.

Patients should be treated for 30 to 90 days before the physician determines the possible benefits of continued therapy. Therapy should be continued as long as the favorable response lasts. Some patients have been maintained on therapy for more than 3 years at doses ranging from 10 to 16 mg per kg of body weight per day.

Estramustine to Treat Prostate Cancer

Estramustine was approved by the US Food and Drug Administration (FDA) in December, 1981 as one of the first drugs in the country to address the disease. It is commercialized under the brand name Emcyt by Pfizer. Orally administered, estramustine is particularly indicated to treat metastatic or progressive prostate cancer. The medicine comes as capsules that should be taken on an empty stomach more than an hour before meals or at least two hours afterwards. Patients are also recommended to take estramustine with plenty of water, but not to mix it with milk. The treatment usually consist on three to four capsules a day typically for cycles of six weeks, followed by breaks of two weeks.


Your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor or pharmacist first.

This drug should not be used with the following medications because very serious interactions may occur: aromatase inhibitors (e.g., anastrozole, exemestane), troleandomycin, tranexamic acid.

If you are currently using any of these medications listed above, tell your doctor or pharmacist before starting this medication.